Janus Henderson Group
MLTX icon

Janus Henderson Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Janus Henderson Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.3M Buy
3,451,628
+1,355,640
+65% +$22.5M 0.03% 358
2025
Q4 		$27.7M Buy
2,095,988
+2,084,888
+18,783% +$24.6M 0.01% 533
2025
Q3 		$79.5K Hold
11,100
– – ﹤0.01% 2394
2025
Q2 		$524K Hold
11,100
– – ﹤0.01% 1927
2025
Q1 		$442K Hold
11,100
– – ﹤0.01% 2023
2024
Q4 		$600K Hold
11,100
– – ﹤0.01% 1947
2024
Q3 		$560K Hold
11,100
– – ﹤0.01% 1980
2024
Q2 		$487K Sell
11,100
-187
-2% -$7.92K ﹤0.01% 2001
2024
Q1 		$567K Buy
11,287
+65
+0.6% +$3.53K ﹤0.01% 1945
2023
Q4 		$677K Sell
11,222
-110
-1% -$5.67K ﹤0.01% 1853
2023
Q3 		$646K Buy
+11,332
New +$626K ﹤0.01% 1798
2021
Q4 		– Sell
-15,168
Closed -$150K – 2572
2021
Q3 		$150K Sell
15,168
-33,095
-69% -$330K ﹤0.01% 2113
2021
Q2 		$497K Hold
48,263
– – ﹤0.01% 1433
2021
Q1 		$493K Sell
48,263
-101,737
-68% -$1.12M ﹤0.01% 1355
2020
Q4 		$1.66M Buy
+150,000
New +$1.59M ﹤0.01% 1152

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group's MLTX Position: Q1 2026 in Review

Janus Henderson Group increased its MoonLake Immunotherapeutics (MLTX) stake by 65% in Q1 2026, buying an estimated $22.5M and bringing the position to 3,451,628 shares worth $64.3M. The position accounts for 0.03% of the portfolio, ranked #358.

Janus Henderson Group first reported a position in MLTX in Q4 2020 and has held it in 15 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Janus Henderson Group held 3,451,628 shares of MoonLake Immunotherapeutics worth $64.3M as of Q1 2026.
  • Janus Henderson Group bought 1,355,640 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $22.5M.
  • MoonLake Immunotherapeutics made up 0.03% of Janus Henderson Group's portfolio in Q1 2026, its #358 holding.
  • Janus Henderson Group first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 15 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.